September 2025, Vol 6, No 3

Groundbreaking advancements in cholangiocarcinoma research, including targeted therapies, immunotherapy innovations, and promising early detection strategies, are highlighted in this issue.

The 2025 Chicago Cholangiocarcinoma Symposium, hosted by Dr Anjana Pillai and Dr Andy Liao, will take place on Friday, September 26, from 8:00 am to 4:00 pm, at the Knapp Center for Biomedical Discovery in Chicago, IL.

The ADJUBIL trial reveals that dual immune checkpoint blockade with durvalumab and tremelimumab without capecitabine offers a promising adjuvant therapy option with minimal toxicity for resectable biliary tract cancer.

Patients with TP53-mutated biliary tract cancer may have poorer prognoses but show enhanced responsiveness to immune checkpoint inhibitors, offering hope for tailored therapeutic strategies.

A novel triplet immunotherapy combining durvalumab, bevacizumab, and tremelimumab shows potential for improving survival in advanced hepatocellular and biliary tract cancers.

A novel bispecific antibody, rilvegostomig, combined with chemotherapy shows promising efficacy and safety in improving outcomes for patients with advanced biliary tract cancer.

Zanidatamab-hrii significantly improves survival in HER2-positive biliary tract cancer, offering new hope for patients with limited second-line treatment options.

Real-world data from US veterans confirm the safety and efficacy of ivosidenib in treating IDH1-mutated cholangiocarcinoma, offering hope for improved outcomes in this challenging cancer.

The TRITICC trial highlights a promising second-line therapy with trifluridine, tipiracil, and irinotecan for advanced cholangiocarcinoma, offering hope after failure of first-line treatment.

A cutting-edge circulating cell-free DNA fragmentomics approach combined with machine learning offers a noninvasive method for early detection of biliary tract cancer.